NCT02528799View on ClinicalTrials.gov

Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 6, 2017

Study Completion Date

January 6, 2017

Conditions
Celiac Disease
Interventions
BIOLOGICAL

Nexvax2

Nexvax2 intra-dermal injections twice weekly

BIOLOGICAL

Nexvax2 placebo

Sodium chloride 0.9% intra-dermal injections twice weekly

Trial Locations (4)

1150

Auckland Clinical Studies Ltd, Auckland

4006

Q-Pharm Pty Ltd., Herston

5000

CMAX, A Division of IDT Australia Ltd, Adelaide

WA 6009

Linear Clinical Research, Nedlands

Sponsors

Lead Sponsor

ImmusanT, Inc.
All Listed Sponsors
lead

ImmusanT, Inc.

INDUSTRY